Articles by tag: adhd-treatment

FDA to review CTx-1301 for ADHD treatment in children

New CTx-1301 with trimodal release provides ADHD symptom control for up to 12 hours. Learn about the FDA decision and PTR technology.

FDA to Review Generic Dexmethylphenidate CTx-1301

FDA to Rule on CTx-1301 May 31 — New ADHD Drug with Up to 12 Hours of Action Without Booster Doses. Learn How This Will Change Therapy for Children and Adults.